Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Microbiome and Cancer

Prof. Dr. Eran Elinav


Humans have co-evolved with complex consortia of viruses, bacteria, fungi, and parasites that colonize mucosal surfaces, particularly the gastrointestinal tract, collectively referred to as the microbiota. In mammals, the microbiota can influence many physiologic processes (including development, metabolism, and immunological functions) and changes in the composition of the microbiota are associated with susceptibility to several diseases, including obesity, asthma, inflammatory bowel disease. Additionally, multiple links between microorganisms and cancer have been shown, with altered local microbiota compositions observed in different types of cancer and, more specifically, pathogens such as Helicobacter pylori, Fusobacterium nucleatum, Salmonella typhi, Epstein–Barr virus and human papilloma virus having been associated with carcinogenesis. In addition to its role in carcinogenesis, the intestinal microbiota continues to be linked to the efficacy and toxicity of immunotherapies such as immune checkpoint inhibitors and allogeneic hematopoietic cell transplantation.

At the Division of Microbiome and Cancer, we study the interactions between the mammalian host, the immune system, and the microbiota. Our purpose is elucidating the roles of these factors in carcinogenesis and efficacy of immunotherapy and discovering novel predictive microbial biomarkers for different cancer types and therapy outcome.

We are using both well-established and cutting-edge wet-lab techniques combined with bioinformatic tools to sequence and analyse the microbiome from the oral cavity and gastrointestinal tract, as well as low-biomass samples such as the pancreas and tumour tissue. We combine this approach with integrated multi-omics characterisation of the hosts immune system.

Using translational research approaches we aim to model microbiota perturbations associated with colorectal cancer, pancreatic cancer, and hematologic malignancies in pre-clinical mouse models to understand the mechanisms of microbiota-host cross-talk in these disorders. We investigate how diet or antibiotic-induced dysbiosis affects carcinogenesis in mouse models and study the role of selected bacterial isolates. We also study the longitudinal cross-talk of anti-cancer therapies - chemo- and immunotherapy - with the microbiota in patients and in laboratory mice. In order to transfer this knowledge back into the clinic for the benefit of patients, we are performing precision medicine-based, clinical studies with patient microbiota interventions using specific dietary modifications (Zeevi et al., Cell 2015) or fecal microbiota transfer (Suez et al., Cell 2018).


Prof. Dr. Eran Elinav
Microbiome and Cancer (D480)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg

Elinav Lab at Weizmann Institute of Science

Selected Publications

  • Suez J, Cohen Y, Valdés-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, Stein-Thoeringer CK, Segal E, Elinav E. 2022. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell, 185(18):3307-28. PMID:35987213
  • Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, Silberberg Y, Atarashi K, Furuichi M, Oka A, Liu B, Fibelman M, Weiner IN, Khabra E, Cullin N, Ben-Yishai N, Inbar D, Ben-David H, Nicenboim J, Kowalsman N, Lieb W, Kario2, Cohen ET, Geffen YF, Zelcbuch L, Cohen A, Rappo U, Gahali-Sass I, Golembo M, Lev V, Dori-Bachash M, Shapiro H, Moresi C, Cuevas-Sierra A, Mohapatra G, Kern L, Zheng D, Nobs SN, Suez J, Stettner N, Harmelin A, Zak N, Puttagunta S, Bassan M, Honda K, Sokol H, Bang C, Franke A, Schramm C, Maharshak N, Sartor RB, Sorek R, Elinav E. 2022. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell, 185(16):2879-98. PMID:35931020
  • Fluhr L, Mor U, Kolodziejczyk AA, Dori-Bachash M, Leshem A, Itav S, Cohen Y, Suez Z, Molina S, Ayalon N, Valdes-Mas R, Hornstein S, Karbi H, Kviatcovsky D, Livne A, Bukimer A, Eliyahu-Miller S, Metz A, Brandis A, Mehlman T, Kuperman Y, Tsoory M, Stettner N, Harmelin A, Shapiro H, Elinav E. 2021. Gut microbiome modulates weight gain in mice after discontinued smoke exposure. Nature, 600 (7890)713-19. PMID: 34880502
  • de Castilhos J, Zamir E, HippchenT, Rohrbach R, Schmidt S, Hengler S, Schumacher H, Neubauer M, Kunz S, Müller-Esch T, Hiergeist A, Gessner A, Khalid D, Gaiser R, Cullin N, BBeuthien-Baumann B, Krämer A, Bartenschlager R, Jäger D, Müller M, Herth F, Duerschmied D, Schneider J, Schmid RM, Eberhardt JF, Khodamoradi Y, Vehreschild MJGT, Teufel A, Ebert MP, Hau P, Salzberger B, Poeck H, Elinav E (co-corresponding last author), Merle U, Stein-Thoeringer CK. 2021. Severe dysbiosis and specific Haemophilus and Neisseria signatures as hallmarks of the oropharyngeal microbiome in critically ill COVID-19 patients. Clinical Infectious Disease, 75(1):e1063-71. PMID:34694375
to top
powered by webEdition CMS